Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.40 |
| ▸ | NQO1 | P15559 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919784 | 0.98 | NR5A1 (0.43) | ALDH1A1KDM4ESMN1; SMN2KCNA3NR5A1 | |
| SCHEMBL921599 | 0.98 | NR5A1 (0.43) | ALDH1A1KDM4ESMN1; SMN2KCNA3NR5A1 | |
| SCHEMBL920256 | 0.98 | NR5A1 (0.43) | ALDH1A1KDM4ESMN1; SMN2KCNA3NR5A1 | |
| SCHEMBL920395 | 0.96 | SMN1; SMN2 (0.42) | ALDH1A1KDM4ESMN1; SMN2KCNA3NR5A1 | |
| SCHEMBL322236 | 0.90 | THRA (0.44) | ALDH1A1KDM4ESMN1; SMN2NQO1L3MBTL1 | |
| SCHEMBL2457210 | 0.88 | KDM4E (0.45) | ALDH1A1KDM4ESMN1; SMN2NQO1L3MBTL1 | |
| SCHEMBL991126 | 0.86 | NR5A1 (0.52) | ALDH1A1SMN1; SMN2NR5A1LTA4HTP53 | |
| SCHEMBL7276161 | 0.85 | NR5A1 (0.55) | ALDH1A1SMN1; SMN2NR5A1LTA4HGAA | |
| SCHEMBL7861362 | 0.85 | NR5A1 (0.55) | ALDH1A1SMN1; SMN2NR5A1LTA4HGAA | |
| SCHEMBL60563 | 0.83 | NR5A1 (0.57) | NR5A1LTA4HGAATP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201649-A1 | AGRICULTURAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2345328-A1 | COMPOSITION FOR AGRICULTURAL USE | Sumitomo Chemical Company, Limited (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20110009454-A1 | COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2248423-A1 | COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS | Sumitomo Chemical Company, Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| CN-1114834-A | antidiabetic agent | OTSUKA PHARMA CO LTD (JP) | 1996-01-10 | — | — | CN | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009454-A1 | COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS | WIZ, TST, NAT1 | ALDH1A1 2743/4885KDM4E 3657/4885SMN1; SMN2 4796/4885 |
| US-20110201649-A1 | AGRICULTURAL COMPOSITION | H1-0, H1-3, H1-2 | ALDH1A1 4326/4885KDM4E 3733/4885SMN1; SMN2 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.